Learn AboutCanniMed Clinical Trials
Ongoing research into the efficacy of medical cannabis is critical, and at CanniMed we are taking a very active role in this endeavour. Our clinical trial program is robust and includes ongoing studies in patients with osteoarthritis of the knee, Tourette’s Syndrome and juvenile epilepsy.
To date, the pharmaceutical-grade cannabis produced by Prairie Plant Systems, under contract with CanniMed® Ltd., has been used in published clinical trial results to demonstrate the efficacy of smoked cannabis for chronic pain.
Our Canadian-grown cannabis has been used in two published clinical trials to date:
A randomised controlled trial of smoked cannabis for chronic neuropathic pain.
The study found that a single inhalation of 25 milligrams of 9.4% THC herbal cannabis three times daily for five days reduced the intensity of pain, improved sleep quality, reduced anxiety and was well tolerated.i
The results of this study were used in the development of the Canadian Pain Society’s Pharmacological management of chronic neuropathic pain: Revised consensus statement positioning medical cannabis as third line treatment for neuropathic pain.ii
iWare, M.A., Wang, T., Shapiro, S., Robinson, A. and others. (2010) Smoked Cannabis for Chronic Pain: a Randomized Controlled Trial. Canadian Medical Association Journal (CMAJ). 182:E694-E701.
iiMoulin, D.E., Boulanger, A., Clark A.J., Dao, T. and others. (2014) Pharmacological Management of Chronic Neuropathic Pain: Revised Consensus Statement from the Canadian Pain Society. Pain Research and Management. Nov-Dec; 19(6): 328–335.
A randomized controlled trial of herbal cannabis on chronic non-cancer pain.
This was the first and largest study looking at the long term safety of medical cannabis use by patients suffering from chronic pain. Patients were given access to herbal cannabis containing 12.5% THC (CanniMed 12.0) and were followed over one year. The researchers found that patients with chronic pain who used cannabis daily for one year, when carefully monitored, did not have an increase in serious adverse events compared to pain patients who did not use cannabis. This study was published in the Journal of Pain.iii
iiiWare, M.A., Wang, T., Shapiro, S. and others. (2015) Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS). The Journal of Pain. Vol 16. Nov 12. http://www.jpain.org/article/S1526-5900(15)00837-8/pdf